Polycystic Ovary Syndrome and BETATROPHIN

Can the Betatrophin be a Reliable Marker of Insulin Resistance in Normal Weight and Overweight Women With Polycystic Ovary Syndrome?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04448730

Enrollment

Registered

2020-06-26

Start date

2018-01-01

Completion date

2019-12-30

Last updated

2020-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Polycystic Ovary

Keywords

Betatrophin, PCOS, obesity, insulin resistance

Brief summary

This is an original study giving an information about the association body mass index, polycystic ovary syndrome and betatrophin.

Detailed description

Introduction: Betatrophin is a protein hormone which has a significant role in glucose homeostasis and lipid metabolism. The aim of this study is to compare the levels of serum betatrophin in overweight and normal weight women with PCOS. Material and Method: Thirty-five patients normal weight women with PCOS (BMI\<25) and 38 obese women with PCOS (BMI≥25) were included in this prospective, cross-sectional study. Patients were selected according to Rotterdam criteria. Serum betatrophin levels were studied by ELISA method and then compared between these two groups besides the following additional parameters as waist circumference/hip circumference ratio, fasting blood glucose, 75 g OGTT (oral glucose tolerance test) results and HOMA-IR levels.

Interventions

DIAGNOSTIC_TESTserum marker levels

two groups comparisons

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

-Polycystic ovary syndrome according to 2003 Rotterdam PCOS Consensus diagnostic criteria

Exclusion criteria

* pregnancy, * an additional systemic disease (i.e.,hyperprolactinemia, thyroid dysfunction, liver or kidney diseases, cardiovascular disease, hyperlipidemia, type 1 or type 2 diabetes, chronic or acute infection within the previous 30 days), * morbid obesity, * smoking, * the use of medications for contraception, androgen excess, hypertension, hyperglycemia or dyslipidemia at least 3 months before the study.

Design outcomes

Primary

Measure	Time frame	Description
serum Betatrophin levels	30 min	ng/L

Secondary

Measure	Time frame	Description
Waist/hip ratio	5 min	centimeter
75 gr OGTT(oral glucose tolerance test)	2 hours	(mg/dl)
BMI (body mass index)	5 minute	kg/m2

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026